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Abstract
We previously demonstrated that infusion of an intestinal peptide called xenin-25 (Xen)
amplifies the effects of glucose-dependent insulinotropic polypeptide (GIP) on insulin secre-
tion rates (ISRs) and plasma glucagon levels in humans. However, these effects of Xen, but
not GIP, were blunted in humans with type 2 diabetes. Thus, Xen rather than GIP signaling
to islets fails early during development of type 2 diabetes. The current crossover study
determines if cholinergic signaling relays the effects of Xen on insulin and glucagon release
in humans as in mice. Fasted subjects with impaired glucose tolerance were studied. On
eight separate occasions, each person underwent a single graded glucose infusion- two
each with infusion of albumin, Xen, GIP, and GIP plus Xen. Each infusate was administered
± atropine. Heart rate and plasma glucose, insulin, C-peptide, glucagon, and pancreatic
polypeptide (PP) levels were measured. ISRs were calculated from C-peptide levels. All
peptides profoundly increased PP responses. From 0 to 40 min, peptide(s) infusions had lit-
tle effect on plasma glucose concentrations. However, GIP, but not Xen, rapidly and tran-
siently increased ISRs and glucagon levels. Both responses were further amplified when
Xen was co-administered with GIP. From 40 to 240 min, glucose levels and ISRs continually
increased while glucagon concentrations declined, regardless of infusate. Atropine in-
creased resting heart rate and blocked all PP responses but did not affect ISRs or plasma
glucagon levels during any of the peptide infusions. Thus, cholinergic signaling mediates
the effects of Xen on insulin and glucagon release in mice but not humans.
Introduction
Xenin-25 (Xen) is a 25-amino acid neurotensin-related peptide produced by a subset of enter-
oendocrine cells [1,2]. In animals, Xen administration delays gastric emptying [3], reduces
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food intake [4–6], increases intestinal motility [7], augments gall bladder contractions [8],
enhances exocrine pancreas secretion [9], and excites a small subset of enteric neurons [10]. We
[11] and others [12] have shown that Xen amplifies the effects of glucose-dependent insulino-
tropic polypeptide (GIP) on insulin secretion in mice. Surprisingly, this in vivo response to GIP
plus Xen was not recapitulated in studies using isolated islets, insulin-producing cell lines, or
the in situ perfused [11]. However, the ability of Xen to amplify GIP-mediated insulin secretion
in vivo was inhibited by atropine. Additionally, in vitro experiments showed that the in vivo
effects of Xen could be mimicked by carbachol. These results indicate that in mice, Xen initiates
a cholinergic relay to islets which in turn, amplifies the effects of GIP on insulin release [11].
Many of the effects of Xen are mediated by activation of neurotensin receptor-1 on neurons
[3,5,6,8,10,13]. Immunohistochemical studies showed that in the human pancreas, neurotensin
receptor-1 is present on nerves, but not islet endocrine cells [14]. In human studies, we showed
that Xen delays gastric emptying [15], increases pancreatic polypeptide release [14,16], inhibits glu-
cagon-like peptide-1 release [15], augments intestinal motility [15,17], and amplifies the effects of
GIP on insulin, glucagon, and pancreatic polypeptide release [14,17]. Contrary to dogma, these
studies also demonstrated that exogenously administered GIP remained fully active in humans
with mild type 2 diabetes mellitus [17]. Conversely, the effects of Xen on GIP-mediated insulin
and glucagon release were greatest in humans with impaired glucose tolerance but blunted in
those with mild type 2 diabetes mellitus [17]. Similarly, we previously showed that the effect of Xen
on GIP-mediated insulin secretion was greater in hyperglycemic compared to normoglycemic
mice [11]. These collective results suggest that increased cholinergic signaling is a compensatory
neural mechanism to increase insulin secretion in pre-diabetes and type 2 diabetes develops if this
adaptation fails. Thus, it is critical to determine if the effects of Xen on insulin and glucagon release
are mediated by cholinergic signaling in humans as in mice. The purpose of the present study is to
determine if atropine inhibits the ability of Xen to amplify the effects of GIP on insulin, glucagon,
and pancreatic polypeptide release in humans. As expected, atropine completely blocked the pan-
creatic polypeptide response to GIP alone, Xen alone, and the combination of GIP plus Xen. Sur-
prisingly and in stark contrast to mice, the effects of Xen on GIP-mediated insulin and glucagon
release were not inhibited by atropine and thus, are not mediated by cholinergic signaling.
Materials and methods
Human subjects
All protocols were approved by Washington University’s Human Research Protection Office
(November 12, 2012) and the FDA (IND#103,374) and are registered with ClinicalTrials.gov
(NCT01951729). The original study protocol as approved by the IRB is presented in S1 Appen-
dix. An administrative error resulted in a delay in registering this clinical trial (all ongoing and
related studies are currently registered). Subjects were recruited through Washington Univer-
sity’s Research Participant Registry, our own database, and by visibility on the Clinicaltrials.
gov website. Studies were performed by the nursing and medical staff in the Clinical Research
Unit of the Institute of Clinical and Translational Sciences of Washington University after
obtaining written informed consent. As part of the consent, participants agreed that if we
write a report or article about this study or share the study data set with others, we will do so in
such a way that they cannot be directly identified. Subject recruitment was initiated on March
13, 2013 and follow-up for the final participant was completed on May 13, 2015. Subjects were
remunerated to encourage completion of the study. An initial screening visit was conducted
after a 10-hour overnight fast. Subjects completed a health history questionnaire, underwent
an EKG, and had blood drawn for screening labs including hematocrit, hemoglobin, HbA1C,
lipid panel, electrolytes, amylase, and thyroid, liver and kidney function. Subjects were
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excluded if they had a history of chronic pancreatitis and/or risk factors for chronic pancreati-
tis, had a history of gastrointestinal disorders, were taking any medication known to affect
glucose homeostasis, or had significant systemic illness including heart, kidney, liver, inflam-
matory or malignant disease. The use of atropine is contraindicated in those with narrow-
angle glaucoma, obstructive uropathy including benign prostatic hypertrophy, pyloric stenosis,
myasthenia gravis, asthma, hyperthyroidism, angina and cardiac arrhythmias including heart
block. Subjects with any of these conditions were also excluded. Subjects who were otherwise
eligible received a standard 75-gram oral glucose tolerance test on a subsequent visit to deter-
mine final eligibility. Impaired glucose tolerance was defined by the 2-hour plasma glucose
level (141 to 199 mg/dl) during the oral glucose tolerance test using diagnostic criteria of the
American Diabetes Association [18]. Male and female subjects with impaired glucose toler-
ance, 18 to 65 years of age, and of all races and ethnicities were eligible. Women of childbear-
ing potential were required to use effective birth control.
Study design
This is a crossover study in which each participant was to undergo 8 separate 240-minute
graded glucose infusions, each separated by at least 2 weeks (Fig 1). Studies were performed
after a 10-hour overnight fast. Subjects were blinded to treatment. One intravenous catheter
was placed into a hand vein. This hand was kept in a thermostatically controlled box (50–55˚C)
to facilitate venous sampling and to provide arterialized venous blood [19]. A second intrave-
nous line was inserted for administration of glucose and study drugs. For each graded glucose
infusion (Fig 2), the intravenous glucose infusion was initiated at time zero and maintained at a
rate of 1 mg x kg-1 x min-1 for 40 min, followed by 2, 3, 4, 6, and 8 mg x kg-1 x min-1 (40 min for
each step) as in our earlier study [17]. Albumin alone (i.e. no peptide), Xen alone, GIP alone,
and GIP+Xen were administered by primed-constant infusions starting at time zero as previ-
ously described [17]. Briefly, a continuous infusion of peptide(s) was maintained at a rate of 4
pmoles x kg-1 x min-1 throughout the experiment. However, a priming dose was administered
during the first 10 minutes by increasing the infusion rate 2.71-fold for the first 3 minutes,
1.93-fold for the next 4 minutes, and 1.41-fold for the final 3 minutes. Albumin alone was
infused at the same rate when peptides were not administered. Each peptide(s) was adminis-
tered both with and without an infusion of atropine sulfate. Dosing for atropine sulfate was
based on a survey of the literature [20–31] and studies registered on the Clinicaltrials.gov web-
site (NCT00468091; NCT00689208; and NCT00992901). Atropine sulfate was administrated by
primed-constant intravenous infusion starting at minus 30 minutes (priming dose of 0.4 mg/m2
over 2 minutes followed by continuous dose of 0.3 mg/m2/hour). Saline alone was infused when
atropine was not administered. Infusion rates for glucose, peptides, and atropine/saline are
shown in Fig 2. The same peptide(s) was administered in 2 successive visits. Atropine was
administered with the peptide on one visit and saline (instead of atropine) was administered
with the same peptide on the subsequent visit. The order of the paired visits was first random-
ized with respect to the peptide(s) after which the order of the atropine or saline infusion was
randomized. This was done to ensure that in case of drop outs, matched infusions (each
peptide ± atropine) would be obtained for each subject. Hemoglobin levels were measured
immediately before each study visit and anyone with a Hb<11.2 g/dL had that study delayed.
Peptides
GIP and Xen were custom synthesized under GMP conditions (Bachem, Torrance, CA), vali-
dated for use in humans, and compounded in normal saline containing 1% Flexbumin (Baxter
Healthcare Corp., Westlake Village, CA) as previously described [17].
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Fig 1. Flow diagram for atropine study. The flow diagram is for a crossover study in humans with impaired glucose
tolerance and was designed so that each subject would receive all 8 graded glucose infusions. The same peptide(s) was
administered during 2 successive visits- once with saline and once with atropine. First, the order of the peptide infusions was
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Blood sampling
Blood was drawn for measurements of plasma glucose and preparation of heparinized plasma
at the following time points (in minutes): -40, -30, -20, -10, 0, 5, 10, 15, 20, 30, 40, 50, 60, 70,
80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240. Blood was col-
lected for preparation of EDTA/Trasylol plasma at -40, -30, -20, -10, 0, 5, 10, 15, 20, 30, 40, 80,
120, 160, 200, and 240 minutes. A DPP4 inhibitor (Millipore, St. Charles, MO) was also
included in the EDTA/Trasylol tubes.
Assays
Glucose, insulin, C-peptide, Xen, total GIP, complete metabolic profiles and hemoglobin
A1c were measured as previously described [32]. Glucagon was measured as previously
described [32] using an ELISA specific for mature glucagon that does not cross-react with
other proglucagon-derived peptides. Pancreatic polypeptide was measured as previously
described and involves an extraction step to remove compounds that interfere with the assay
[14].
randomized. Second, the order of saline or atropine administration was randomized for each peptide. For example, if the
subject was randomized to first receive Xen alone, this person would receive Xen in study visits 1 and 2. The atropine and
saline infusions would then be randomized to visit 1 and 2. Eight subjects received all 8 graded glucose infusions. One
subject received 6 infusions but did not receive either infusion with Xen alone. One subject received only the 2 infusions
with GIP plus Xen.
https://doi.org/10.1371/journal.pone.0192441.g001
Fig 2. The graded glucose infusion protocol. The glucose infusion rate was increased in a step wise fashion every 40
minutes starting at time zero as shown in red. The primed-constant infusion of each peptide(s) was started at time zero
and is shown in yellow. Note that GIP and Xen were each infused at the same rate when administered together. The
primed-constant infusion of atropine (or saline) was initiated 30 minutes before the start of the graded glucose infusion as
shown in blue. All infusions were terminated 240 minutes after the glucose infusion was initiated.
https://doi.org/10.1371/journal.pone.0192441.g002
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Calculations and data analysis
ISRs were derived by stochastic deconvolution of the peripheral C-peptide concentrations as
in earlier studies [15–17,32] using population-based estimates of C-peptide clearance kinetics
[33–35]. Baseline values for glucose, ISR, and pancreatic polypeptide are mean values for the
-50, -40, -30 time points. Baseline for glucagon are mean values of -30, -20, and -10 time points
because baseline values continually dropped from -50 to -30 minutes and the decline was not
affected by atropine. Baseline levels for each individual were used for their respective calcula-
tions. AUCs were calculated for each individual using the trapezoid method and incremental
AUCs were determined by subtracting that individual’s baseline AUC from the AUC. Data for
AUCs and iAUCs were analyzed using mixed effects models with subject as a random effect
and treatment as a fixed effect using SAS v9.4. Baseline values were used as a covariate for the
analysis of the AUCs. Data for the time frames of 0 to 40 minutes and 40 to 240 minutes were
analyzed separately because the former represents a rapid, large, and transient response and
the latter is a progressively changing effect. Thus, the early and late responses may be regulated
by distinct mechanisms. Outcome measures through time were analyzed using the mixed ran-
dom effects repeated measures model with covariance structure estimated by a spatial model
(SAS 9.4). Subject and subject by drug interaction were random effects. Individual data points
used for calculating means, (incremental) areas under the curve, and variance measures are
provided in the S2 Appendix.
Results
Subject characteristics
We previously demonstrated [17] that the ability of Xen to amplify the effects of GIP on insulin
and glucagon release is greatest in humans with impaired glucose tolerance and therefore, only
subjects with impaired glucose tolerance were studied. Fifty three subjects were screened and
15 were enrolled and studied on at least 1 occasion (Fig 1). Most screen failures were due to
subjects not meeting the criteria for impaired glucose tolerance (see below) or having a contra-
indication for receiving atropine. Six patients were withdrawn from the study and data from
these participants were not included in the analyses. Data from the 9 remaining subjects were
analyzed. Clinical characteristics and demographics for these 9 subjects are shown in Table 1.
Seven of the participants completed all 8 visits. One subject was dropped before both Xen infu-
sions due to change in medication and one was dropped after both GIP plus Xen visits due to
anxiety. Consistent with the screening protocol, all subjects had impaired glucose tolerance
based on the 2-hour glucose value from a standard 75-gram oral glucose tolerance test.
Table 1. Subject demographics and clinical characteristics.
Parameter n = 9
2-Hour Glucose (mg/dl) 170± 20
HbA1c (%) 6.0 ± 0.4
Fasting Glucose (mg/dl) 99.3 ± 7.8
Fasting Insulin (μU/ml) 11.4 ± 4.9
HOMA-IR 2.8 ± 1.3
BMI, kg/m2 30.4 ± 8.2
Age (years) 46 ± 10
Gender (F/M) 6/2
Values except gender are group mean ± SD.
https://doi.org/10.1371/journal.pone.0192441.t001
Effects of cholinergic signaling on islet hormone release
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Peptide levels during infusion of GIP and/or Xen
Steady-state levels of GIP and/or Xen are attained approximately 10 minutes after starting the
primed-constant peptide infusions and are maintained until the end of the graded glucose infu-
sion [17]. As in our earlier study, infusion of GIP increased steady state levels of plasma GIP
from ~25 pM to ~400 pM whereas infusion of xenin-25 increased plasma xenin levels from the
lower limit of detection to ~200 pM (Fig 3). Infusion of one peptide did not affect plasma levels
of the other. Further, infusion of atropine did not affect plasma levels of either peptide. Thus,
pharmacologic levels of GIP and/or Xen were attained throughout the graded glucose infusions.
Atropine increases resting heart rate
In the absence of atropine, infusion of Alb alone or Xen alone had little effect on resting heart
rate (Fig 4). As in our earlier study [17], infusion of GIP alone increased resting heart rate by
Fig 3. Peptide levels during graded glucose infusions. Subjects were administered 8 different graded glucose
infusions, each on a separate day. Each visit was separated by at least 2 weeks. Glucose and peptides were infused from
0 min to 240 min and atropine (or saline control) was infused from -30 to 240 min as shown in Fig 2. Steady state levels
of immunoreactive-GIP (IR-GIP; panel A) and immunoreactive-Xen (IR-Xen; panel B) were measured during
infusion with albumin alone (Alb), Xen alone, GIP alone, and the combination of GIP plus Xen (G+X). Each peptide
was measured during infusion of atropine or the saline control. Because of limiting sample volumes, GIP and Xen were
measured only in the 80 or 240 minute samples, respectively. Values represent group means ± SEM.
https://doi.org/10.1371/journal.pone.0192441.g003
Effects of cholinergic signaling on islet hormone release
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~9 beats per minute and this response was not amplified when Xen was administered along
with GIP. Infusion of atropine increased resting heart rate before peptides were administered
(i.e. from -30 to 0 minutes) as well as after the peptide infusions were initiated. Heart rate was
normalized ~90 minutes after the atropine infusion was terminated. Mean arterial pressures
were unaffected by atropine (Not Shown) although infusion of GIP, alone or with Xen, de-
creased mean arterial pressure by ~10 mm Hg as in our earlier study [17]. Based on symptom
surveys self-reported by subjects before, during, and after the infusions, xerostomia was expe-
rienced by all subjects during 1 or more of the 4 atropine infusions (mean = 2.6; SD = 1.1).
Blurred vision was self-reported by 3 of the 9 subjects during 2 (n = 2) or 3 (n = 1) of the
Fig 4. Atropine increases resting heart rate. Resting heart rate was measured at the indicated times before, during and after
the graded glucose infusion (GGI) with Alb alone (PanelA), Xen alone (Panel B), GIP alone (Panel C), and GIP plus Xen (G+X;
Panel D). Atropine or saline infusion was started 30 minutes before the graded glucose infusion. Note that atropine or GIP
increased resting heart and values were normalized approximately 90 minutes after the graded glucose infusions were terminated.
After 240-minutes, heart rates increase in the subjects administered saline instead of atropine because they are no longer confined
to the bed. Values represent group means ± SEM.
https://doi.org/10.1371/journal.pone.0192441.g004
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atropine infusions. These results indicate that atropine dosing was effective in our patient
population.
Peptides increase cholinergic signaling in humans
As reported earlier [14], infusion of peptide(s) alone, but not albumin alone, rapidly increased
pancreatic polypeptide concentrations after which the levels slowly declined but remained ele-
vated for the duration of the graded glucose infusion (Fig 5A). The pancreatic polypeptide
response was greatest during infusion of GIP+Xen compared to GIP alone and Xen alone. The
pancreatic polypeptide response to GIP was delayed compared to that with Xen alone. All pep-
tide-dependent increases in pancreatic polypeptide levels were abolished when atropine was
administered during the graded glucose infusion (Fig 5B). Like the temporal profiles, pan-
creatic polypeptide AUCs (Fig 5C) and iAUCs (Fig 5D) were also increased in the order of
Fig 5. Atropine inhibits pancreatic polypeptide release. Panels A and B. Pancreatic polypeptide (PP) levels were measured at the
indicated times before and during graded glucose infusions (GGIs) in the presence of the indicated peptide(s) and with infusion of
saline (Panel A) or atropine (Panel B). Total (Panel C) and incremental (Panel D) AUCs from 0–240 minutes were calculated from
data in panels A and B. Incremental and total AUCs were determined for each individual and values represent group means ± SEM.
Significance was determined using the mixed effects model. p values for each peptide versus albumin alone are indicated within
charts in Panels C and D. p values for the effects of atropine for each peptide infusate (or albumin control) are indicated below
Panels C and D. The p values for infusate effects were calculated for all 8 treatments. Note that atropine infusion completely blocks
all pancreatic polypeptide responses.
https://doi.org/10.1371/journal.pone.0192441.g005
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GIP+Xen > GIP alone>Xen alone > Alb alone and the increases were completely blocked by
atropine (p<0.003 and<0.006 for respective infusate effects). Thus, peptide(s) infusions
increase cholinergic signaling in humans.
Cholinergic signaling does not mediate the effects of peptides on insulin
secretion
As in our earlier study [17], plasma glucose levels remained nearly euglycemic for the first 40
minutes of the graded glucose infusion in the presence or absence of peptide(s) (Fig 6A). In
contrast, there was a rapid, large, and transient increase in ISRs over this same period during
infusion of GIP alone, but not Xen alone, and this transient response was even greater when
Xen was administered along with the GIP (Fig 6B). These early insulin secretory responses
occur in the absence of a significant increase in plasma glucose levels (Fig 6C). The rapid and
transient increases in ISRs were quantified by determining AUCs for ISRs for the time frame
of 0–40 min. In agreement with the temporal data in Fig 6, both the incremental (Fig 7A) and
total (Fig 7B) AUCs were respectively increased 3-fold (p = 0.007) and 1.5-fold (p = 0.003) by
infusion of GIP alone, but not Xen alone. Administration of the combination of GIP plus Xen
increased the early ISR response for both incremental (4.3-fold) and total (1.8-fold) AUCs;
(p<0.0001 for both; Fig 7A and 7B). Over this first 40 minutes, the effects of peptides on the
profiles for plasma glucose levels and ISRs were similar with (Fig 6D–6F) and without (Fig
6A–6C) infusion of atropine. Similarly, the ISR iAUCs and AUCs for each peptide over the
first 40 minutes of the graded glucose infusions were unaffected by atropine (Fig 7A and 7B).
These results indicate the rapid and transient insulin secretory response to peptides is not
mediated by cholinergic signaling.
After the first 40 minutes of the graded glucose infusions, both plasma glucose (Fig 6A and
6D) and ISRs (Fig 6B and 6E) progressively increased such that ISR as a function of plasma
glucose increased linearly in the order of GIP+Xen > GIP alone> xenin alone or albumin
alone (Fig 6C and 6F). Because peptides affected the 40 minute values for ISR versus plasma
glucose (Fig 6C and 6F), the later ISR responses were quantified by determining incremental
and total AUCs for ISR and plasma glucose levels (from 40–240 min for both outcomes) and
then calculating the ratio of ISR to glucose. Results revealed that infusion with GIP alone, but
not Xen alone, amplified the ISR/glucose incremental (Fig 7C) and total (Fig 7D) AUCs
1.55-fold (p = 0.0048) and 1.17-fold (p = 0.042), respectively and amplification was further
increased to 1.70-fold (p = 0.0005) and 1.27-fold (p<0.001), respectively by infusing the com-
bination of GIP plus Xen. The 40 to 240 minute ISR/glucose responses to peptides were not
inhibited by atropine indicating that they are not mediated by cholinergic signaling.
Cholinergic signaling does not mediate the effects of peptides on glucagon
levels
Our earlier study showed that GIP transiently increases plasma glucagon levels as well as ISRs
over the first 40 minutes of the graded glucose infusion and these responses were amplified by
Xen only in subjects without type 2 diabetes mellitus [17]. Thus, the effects of peptides and
atropine on plasma glucagon levels were determined (Figs 8 and 9). As in our earlier study,
infusion of GIP alone increased plasma glucagon levels at the 40 min time point after starting
the graded glucose infusion (p = 0.07) and the glucagon response at the 40 min time point was
further enhanced when Xen was infused along with the GIP (p<0.001; Figs 8A and 9A). In the
current study, additional samples were collected from 0 to 40 minutes to define this early glu-
cagon response in greater detail. During infusion with albumin alone, plasma glucagon levels
progressively declined starting as soon as the graded glucose infusion was initiated (Fig 9A
Effects of cholinergic signaling on islet hormone release
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Fig 6. Xen amplifies the effects of GIP on ISRs. Graded glucose infusions (GGIs) with the saline control (Panels A-C) or atropine infusion
(Panels D-F) were conducted. Plasma glucose (Panels A and D) and ISRs (Panels B and E) are shown for the indicated times before and during
GGIs. The glucose infusion rate (GIR) at each 40 minute step is shown in white. Note that plasma glucose levels increase progressively even
though glucose was administered in a step-wise fashion. Data from panels A and B are re-graphed in panel C whereas data from panels D and E
are re-graphed in panel F. Symbols and error bars are eliminated in panels C and F for clarity. The rapid and transient increases in ISR in
response to GIP and GIP plus Xen from 0–40 minutes (Panels B and E) are reflected by the initial spikes in ISRs (Panels C and F) that occur in
the absence of a significant increase in plasma glucose levels. Values represent group means ± SEM.
https://doi.org/10.1371/journal.pone.0192441.g006
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and 9B). As noted for ISRs, infusion with GIP+Xen caused a rapid and transient increase in
plasma glucagon levels (Fig 9A). This response was highly significant from 5 to 40 minutes
after starting the graded glucose infusion when compared to that with albumin alone. The
rapid glucagon responses to GIP alone and Xen alone were smaller and neither reached statis-
tical significance (Fig 9A). Infusion of atropine did not affect plasma glucagon levels during
infusion of albumin alone or any peptide(s) (Fig 9B–9E). From 40 to 240 minutes, plasma glu-
cagon levels progressively decreased as plasma glucose levels increased (Fig 8). This decrease
was observed regardless of which peptide(s) was administered indicating that it may be a glu-
cose-regulated rather than a peptide-dependent response. As with the early response, the 40 to
240 minute glucagon responses to albumin and peptides were unaffected by atropine (Fig 9).
These results indicate that cholinergic signaling does not mediate the effects of peptides on the
glucagon response.
Discussion
Transmitters and peptides released from neurons that innervate islets play important roles in
regulating insulin and glucagon release [36,37]. In general, parasympathetic and sympathetic
Fig 7. Atropine does not inhibit effects of peptides on ISRs. Incremental (Panels A and C) and total (Panels B and D) AUCs were
calculated using data shown in Fig 6. Baseline values (average from -50 to -30 min) were subtracted to calculate incremental AUCs.
Outcomes were determined for each individual and values represent group means ± SEM. Significance was determined using the mixed
effects model. Panels A and B: Data are for 0–40 min (Panels A and B). Panels C and D: Data are for 40–240 min. Values were calculated
from the 40 to 240 ISR (i)AUCs for each individual divided by the 40 to 240 glucose (i)AUCs for the same individual. Values represent
group means ± SEM.
https://doi.org/10.1371/journal.pone.0192441.g007
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Fig 8. Xen amplifies the rapid and transient response to GIP via a muscarinic receptor-independent mechanism. Panels
A and B: Plasma glucagon levels were measured at the indicated times during graded glucose infusions (GGIs) with the
Effects of cholinergic signaling on islet hormone release
PLOS ONE | https://doi.org/10.1371/journal.pone.0192441 February 21, 2018 13 / 20
neurons that innervate pancreatic islets increase and inhibit insulin release, respectively [36–
39]. In rodents, islets are richly innervated by parasympathetic neurons [40]. Many studies
with genetically modified mice and/or islets indicate that cholinergic signaling via M3 musca-
rinic acetylcholine receptors plays an important role in regulating insulin and glucagon release
[41–46]. Consistent with these results, we previously showed in hyperglycemic mice that Xen,
with GIP but not alone, indirectly amplifies insulin secretion by initiating a cholinergic neural
relay to islets [11]. As shown earlier [14,17] as well as in this paper, Xen amplifies the effects of
GIP on insulin, glucagon, and pancreatic polypeptide release during graded glucose infusions
in humans without type 2 diabetes mellitus. Although atropine completely inhibited the pan-
creatic polypeptide responses to Xen alone, GIP alone, and the combination of GIP plus Xen,
it had little effect on rapid and transient (0 to 40 minutes) and glucose-regulated (40 to 240
minutes) insulin and glucagon responses, regardless of peptide(s) administered. Consistent
with these results, we recently demonstrated that bethanechol, a muscarinic acetylcholine ago-
nist that works only in the periphery, increased the postprandial pancreatic polypeptide
response in humans with impaired glucose tolerance but had no effect on ISRs or plasma glu-
cagon levels [16]. Similarly, Xen infusion increased the postprandial pancreatic polypeptide
response 6-fold in humans with normal glucose tolerance, impaired glucose tolerance, and
type 2 diabetes mellitus [16] without affecting ISRs or plasma glucagon levels [15]. Thus, our
collective studies strongly suggest that cholinergic signaling plays an important role in regulat-
ing insulin and glucagon release in mice, but not humans.
An immunohistochemical study suggested that mouse, but not human, islets are richly
innervated with parasympathetic neurons [40]. However, studies with the isolated perfused
human pancreas have shown that electrical stimulation of the splanchnic nerve in the presence
and absence of selective neural inhibitors increases both cholinergic and sympathetic input to
islets which in turn, regulates insulin, glucagon, pancreatic polypeptide, and somatostatin
release [47–52]. Further, neurotransmitters can regulate insulin release in isolated human islets
[53]. Thus, functional neural/cholinergic signaling can regulate islet physiology in humans.
This also suggests that under physiologic conditions and in the intact human, insulin secretion
and glucagon release are regulated by numerous factors and studying the effects of single com-
ponents in isolation may not reflect what happens in whole person physiology.
The specific pathway(s) that mediates the effects of Xen on islet physiology in humans is
unknown. We have shown that neurotensin receptor-1, the major receptor for Xen, is present
on nerves, but not endocrine cells, in the human pancreas [14]. In addition to parasympathetic
neurons, Kirchgessner and Gershon have described an extensive network of enteric neurons
that directly connect the proximal small intestine and pancreas [54–57]. These neurons can
function independently of the central nervous system and are capable of modifying pancreatic
islet function. We have shown that Xen excites a small subset of enteric neurons [10] raising
the possibility that enteric neurons may play an underappreciated but important role for regu-
lating islet physiology. It will be important to determine the specific neural or non-neural path-
way that mediates the effects of Xen because this pathway is blunted in type 2 diabetes.
indicated peptide(s) and with the saline infusion (Panel A) or atropine infusion (Panel B). The glucose infusion rate (GIR)
for each 40 minute step is shown in white. Note the rapid and transient increase in glucagon levels during peptide infusions
only from 0 to 40 minutes. Panels C and D: Plasma glucagon levels during graded glucose infusions with saline (Panel C) or
atropine (Panel D) infusions were plotted as a function of plasma glucose levels. Panels E-H: Plasma glucagon and glucose
levels were determined during graded glucose infusions with Albumin alone (Panel E), Xen alone (Panel F), GIP alone
(Panel G), and the combination of GIP plus Xen (Panel H). Plasma glucagon versus glucose values during infusion of saline
or atropine are shown for each peptide(s). Note that atropine had little effect on the rapid and transient (0 to 40 min) or on
the glucose-regulated (40–240 min) glucagon responses regardless of the peptide administered.
https://doi.org/10.1371/journal.pone.0192441.g008
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It is generally accepted that as plasma glucose levels rise, insulin secretion increases while
glucagon release decreases. Our previous [15,17,32] and current studies indicate that the rela-
tionship between insulin and glucagon release is more complicated than this. For examples: i)
insulin secretion and glucagon release are both rapidly and transiently increased while plasma
glucose levels remain nearly euglycemic during the first 40 minutes of graded glucose infusions
with GIP alone or GIP+Xen (Figs 6–9; [17]). Although the glucose concentration within the
Fig 9. Atropine does not inhibit the glucagon response to peptides. Data from Fig 8A and 8B representing the rapid and transient
responses (0 to 40 minutes) were replotted. Panel A: Note that compared to albumin alone, the increase in plasma glucagon is highly
significant during infusion of GIP+Xen from 5 to 40 minutes. Red #, , , and  represent p<0.03,<0.01,<0.001, and<0.0001,
respectively compared to albumin alone. The yellow + sign indicates a p value<0.07 for GIP alone compared to albumin alone.
Panels B-E. Data from graded glucose infusions with albumin alone (Panel B), Xen alone (Panel C), GIP alone (Panel D) and GIP
+Xen (Panel E) are shown for infusions with (red squares) and without (blue circles) atropine. Compared to the saline control,
atropine had no statistically significant effect on the glucagon response to any of the 4 peptide treatments.
https://doi.org/10.1371/journal.pone.0192441.g009
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islets during the start of the graded glucose infusion is unknown, our results strongly suggest
that this rapid response to peptides is largely independent of circulating plasma glucose levels.
Consistent with this hypothesis, others have shown that GIP can increase glucagon release dur-
ing euglycemia [58]. ii) plasma glucagon levels and ISRs both increase for the first 30 minutes
after ingestion of a liquid mixed meal in humans with normal glucose tolerance, impaired glu-
cose tolerance, and type 2 diabetes mellitus [15]; and iii) the paradoxical postprandial increases
in both insulin and glucagon levels are greatly exaggerated in humans with prior Roux-en-Y
gastric bypass [32]. These results suggest that the early release of both insulin and glucagon
may be critical for maintaining postprandial glucose homeostasis distinct from their individual
and well-established respective roles for increasing glucose clearance and augmenting glucose
production. Intriguingly, the combination of insulin plus glucagon has been shown to syner-
gistically increase hepatic FGF21 mRNA levels and peptide release [59]. FGF21 has numerous
beneficial metabolic effects in both rodents and primates [60,61]. The FGF21 response in hepa-
tocytes occurs over several hours rather than minutes [59] suggesting it could mediate delayed
responses to the rapid increases in both insulin and glucagon. Additional signaling molecules
are likely to be regulated by the combination of insulin plus glucagon and these factors could
play important roles in rapid as well as longer-term metabolic responses.
Two limitations to our study should be addressed. First, our mouse studies suggested that
atropine would completely block the effect of Xen on GIP-mediated ISRs and glucagon levels
[11]. Thus, our human study was not powered to detect small effects of atropine on ISRs and
plasma glucagon levels. However, atropine increased resting heart rate and completely blocked
the ability of Xen to increase pancreatic polypeptide release. Thus, the atropine dosing was
effective and muscarinic receptor signaling is most likely involved in only a subset of responses
to Xen. Second, the current study was performed using graded glucose infusions in humans
with impaired glucose tolerance. Thus, it is possible that other techniques or patient popula-
tions would yield different results. However, as previously discussed, Xen infusions and/or
oral bethanechol also increased postprandial cholinergic signaling in humans with normal glu-
cose tolerance, impaired glucose tolerance, and type 2 diabetes mellitus without affecting ISRs
or glucagon levels [16]. Thus, our results appear to be generally relevant but may not be valid
for all pathological conditions.
Conclusions
In spite of the study limitations, our results indicate that in contrast to mice, cholinergic signal-
ing plays a minor role in regulating ISRs and glucagon levels in humans and further illustrate
the importance of studying islet physiology in vivo and in humans. It will be important to
identify the neurotransmitters or neuropeptides that mediate the effects of Xen on insulin and
glucagon release in humans because signaling pathways initiated by Xen rather than GIP fail
early during the development of type 2 diabetes mellitus.
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